TREATMENT OF METASTATIC COLORECTAL CANCER
Review of recent advances

Sharlene Gill, MD, MPH, FRCPC

An estimated 19,600 new cases of colorectal cancer (CRC) will be diagnosed in Canada in 2005,1 and 25% of patients will exhibit metastatic disease at presentation. An additional 30% of those with localized resectable disease will subsequently develop metastatic recurrence.

 

To view the complete article click here (pdf format)
Back to Top of Page  

 

 
 
 
Top-line summary
Colorectal cancer ranks second as a cause of cancer death in Canadian men and third in women.1 Unfortunately, metastatic disease—either present at diagnosis or recurring following resection—occurs in a significant proportion of patients. The last few years have seen important advances in the treatment of metastatic colorectal cancer (MCRC), including introduction of regimens based on oxaliplatin, irinotecan, oral capecitabine, and the monoclonal antibodies cetuximab and bevacizumab. Here, Oncology Exchange reviews notable recent developments in the management of metastatic colorectal cancer, including chemotherapy as first-line, second-line and neoadjuvant treatment, and the integration of targeted therapies into existing regimens.
 
© Parkhurst Publishing Privacy Statement
Legal Terms of Use
Site created by Spin Design (514) 995-4398